Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.57 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.57 |
| ▸ | STK10 | O94804 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.57 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444158 | 1.00 | EGFR (0.60) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL4475255 | 0.85 | EGFR (0.65) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL20605530 | 0.82 | EGFR (0.60) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL4466078 | 0.81 | EGFR (0.59) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL4475881 | 0.80 | ERBB2 (0.60) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL19154550 | 0.80 | EGFR (0.75) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL17243600 | 0.79 | EGFR (0.83) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL18211401 | 0.78 | EGFR (0.86) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL24167354 | 0.78 | ERBB2 (0.71) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL30137776 | 0.78 | ERBB2 (0.71) | EGFRERBB2NQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021144360-A1 | SMALL MOLECULE CSF-1R INHIBITORS IN THERAPEUTIC AND COSMETIC USES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-22 | — | — | WO | claimed |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| WO-2021144360-A1 | SMALL MOLECULE CSF-1R INHIBITORS IN THERAPEUTIC AND COSMETIC USES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-22 | — | — | WO | disclosed |
| US-20210008023-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10780073-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014175444-A1 | ANTI-NLRR1 ANTIBODY | 千葉県 (JP) | 2014-10-30 | — | — | WO | disclosed |
| US-8648087-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120052061-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | TRAGARA PHARMACEUTICALS INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120052061-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | TRAGARA PHARMACEUTICALS INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110301169-A1 | Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites | TRAGARA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110301169-A1 | Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites | TRAGARA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ARRAY BIOPHARMA, INC. | 2011-02-10 | — | — | US | disclosed |
| EP-1971601-B1 | N4-PHENYL-QUINAZOLINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC (US) | 2009-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008023-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | EGFR 4/4885ERBB2 2/4885ABCB11 3116/4885 |
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | EGFR 4/4885ERBB2 2/4885ABCB11 3246/4885 |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | EGFR 2297/4885ERBB2 1593/4885ABCB11 537/4885 |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ERBB4, ERBB2, ERBB3 | EGFR 4/4885ERBB2 2/4885ABCB11 3246/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | EGFR 1810/4885ERBB2 2165/4885ABCB11 275/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | EGFR 2297/4885ERBB2 1593/4885ABCB11 537/4885 |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | EGFR 4/4885ERBB2 2/4885ABCB11 3246/4885 |
| US-20110301169-A1 | Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites | PTGS2, PTGES2, PTGER2 | EGFR 2749/4885ERBB2 1835/4885ABCB11 328/4885 |
| US-20120052061-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | ERBB2, PTGER2, PTGS2 | EGFR 6/4885ERBB2 1/4885ABCB11 4485/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | EGFR 1810/4885ERBB2 2165/4885ABCB11 275/4885 |
| US-10780073-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | EGFR 4/4885ERBB2 2/4885ABCB11 3246/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | EGFR 2109/4885ERBB2 2467/4885ABCB11 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.